Exon Array Biomarkers for the Differential Diagnosis of Schizophrenia and Bipolar Disorder

Marquis Philip Vawter\textsuperscript{a} Robert Philibert\textsuperscript{b} Brandi Rollins\textsuperscript{a} Patricia L. Ruppel\textsuperscript{c} Terry W. Osborn\textsuperscript{d}

\textsuperscript{a}Functional Genomics Laboratory, Department of Psychiatry, University of California, Irvine, CA, USA; \textsuperscript{b}Department of Psychiatry, University of Iowa, Iowa City, IA, USA; \textsuperscript{c}Innovative Analytics, Inc., Kalamazoo, MI, USA; \textsuperscript{d}Laguna Diagnostics, LLC, The Villages, FL, USA

Keywords
Biomarker · Bipolar I disorder · Schizophrenia

Abstract
This study developed potential blood-based biomarker tests for diagnosing and differentiating schizophrenia (SZ), bipolar disorder type I (BD), and normal control (NC) subjects using mRNA gene expression signatures. A total of 90 subjects (n = 30 each for the three groups of subjects) provided blood samples at two visits. The Affymetrix exon microarray was used to profile the expression of over 1.4 million probesets. We selected potential biomarker panels using the temporal stability of the probesets and also back-tested them at two different visits for each subject. The 18-gene biomarker panels, using logistic regression modeling, correctly differentiated the three groups of subjects with high accuracy across the two different clinical visits (83–88% accuracy). The results are also consistent with the actual data and the “leave-one-out” analyses, indicating that the models should be predictive when applied to independent data cohorts. Many of the SZ and BD subjects were taking antipsychotic and mood stabilizer medications at the time of blood draw, raising the possibility that these drugs could have affected some of the differential transcription signatures. Using an independent Illumina data set of gene expression data from antipsychotic medication-free SZ subjects, the 18-gene biomarker panels produced a receiver operating characteristic curve accuracy greater than 0.866 in patients that were less than 30 years of age and medication free. We confirmed select transcripts by quantitative PCR and the nCounter\textsuperscript{®} System. The episodic nature of psychiatric disorders might lead to highly variable results depending on when blood is collected in relation to the severity of the disease/symptoms. We have found stable trait gene panel markers for lifelong psychiatric disorders that may have diagnostic utility in younger undiagnosed subjects where there is a critical unmet need. The study requires replication in subjects for ultimate proof of the utility of the differential diagnosis.

Introduction

Schizophrenia (SZ) and bipolar disorder (BD) are chronic, severe, and disabling brain disorders that affect about 1 and 2%, respectively, of the US population aged 18 years and older. Despite moderately effective treat-
ments such as antipsychotic medications and psychosocial interventions, people with SZ and BD often do not receive timely treatment because the disorder is not correctly recognized. As a result, patients experience multiple hospitalizations and incur socioeconomic disadvantages that can last for decades.

Ideally, successful diagnostic tests could address the significant clinical problem of early identification and differential diagnosis and permit more timely initiation of treatments. Currently, there are no approved clinical diagnostic tests for psychiatric disorders, with diagnosis and treatment being based on the patient’s report of symptoms along with clinical observations. Consequently, clinicians frequently fail to recognize initial presentations of SZ and BD.

These failures may lead to devastating consequences. Following an initial episode of psychosis among individuals aged 16–30 years, there is a 24-fold increase in the risk of death in the following year [1]. This study points towards a lack of treatment (61% did not receive any antipsychotic medication) after initial presentation with psychosis and even higher rates in those dying within 12 months of an initial episode of psychosis [1]. A panel of biomarkers would meet an unmet clinical need to help establish rapid and informative patient decisions. A clinical utility that might be derived from this work is establishing a biomarker panel for determining the psychosis risk state and which subjects may convert to SZ or BD [2]. An index of psychosis based upon a biomarker panel could be useful in evaluating a long-term response to treatments [3].

Conceivably, a panel of RNA biomarkers could address that need. A growing body of work has demonstrated the potential utility of RNA diagnostic tools with peripheral samples such as whole blood, peripheral blood mononuclear cells (PBMCs), and lymphoblastic cell lines in multiple studies of SZ and BD [4–12]. There have also been large studies that have used whole genome RNA expression to compare healthy controls and patients with disorders such as Alzheimer disease [13], autism [14], Down syndrome [15], epilepsy [16], Tourette syndrome [16], Huntington disease [17], Klinefelter syndrome [18], multiple sclerosis [19], smoking and major depression [20], panic disorder [21], posttraumatic stress disorder [22], and subjective social isolation (loneliness) [23]. The success in these studies suggests the possibility that similar approaches could be used to identify RNA profiles for the diagnosis of SZ and BD. Dysregulation of mRNA could potentially help to define sets of genes relevant to the diseases’ pathophysiology and treatment or secondary to their causes.

We hypothesized that for SZ and BD there are unique and global sets of chronic, differentially expressed genes in blood for each disorder. Our hypothesis is based on the concept that circulating blood reflects the changing health of the body, i.e., the “sentinel principle” [24]. As blood circulates through the brain, communication occurs between cells in the blood and the brain [25]. Following a brain injury, neutrophils, macrophages, lymphocytes, and dendritic cells can extravasate into the brain from the blood [26]. These extravasated cells can induce changes in gene expression and proteins as reported in neuroimmunological studies [27, 28]. In prior work using blood-brain samples from the same subjects, about 20% of the transcriptome was expressed at comparable levels and significantly correlated in both tissues from the same subjects [29]. This correlation supports the idea that important biomarkers of either SZ or BD could be expressed peripherally, and these would also have a connection to the central modulation of neuroimmune responses. The advantages of a peripheral transcriptomic study are the ease of access to whole blood and the fact that immune genes are highly expressed. For example, multiple HLA region genes with genome-wide significance are expressed in peripheral blood samples, such as C4 [30] and HLA-DPA1 [31].

Although investigations of biomarkers for SZ and BD have been ongoing for at least a decade [7, 8, 32], there are no widely replicated studies using peripheral blood gene expression [11, 33–42]. A recent mega-analysis of blood samples comparing SZ cases and controls was conducted on a total of 578 subjects in 9 studies. The mega-analysis of the blood transcriptome showed that 220 genes reached a Bonferroni-corrected level of significance [35], indicating the utility of analysis of the blood transcriptome for finding differentially expressed genes. The stability of this potential dysregulation has not been tested across different time points.

The objective of the present study was to test subjects at multiple time points by enrolling SZ (n = 30), BD (n = 30), and normal control (NC; n = 30) subjects characterized at one clinical site to eliminate potential sources of variation. The expression levels of panels of genes were used to define with which disorder the patient was diagnosed with the highest likelihood. We have previously validated Tempus Blood RNA tubes and Affymetrix exon arrays in a study that measured the sources of variation for 8 healthy controls at 9 sequential blood draws every 6 h [29] for 54 h. The resulting data showed that about 20% of the transcripts measured on the Affymetrix exon array did not significantly change over the 9 blood draws.
using Bonferroni correction during the 54-h period. The remaining 80% of the transcripts had changed significantly during this 54-h experiment [29]. Taken together, it is expected that at least 20% of transcripts will be stable over longer periods of time and do not significantly fluctuate by the time of day of the blood draw.

These data reinforce the purpose of the present study to test whether stable expression of genes occurs over months instead of days, so that they can be used as biomarkers for SZ and BD for a differential diagnosis from controls and each other. In this study, RNA expression was measured by the Affymetrix exon array 1.0 ST for biomarker screening. Exon arrays have been widely used for the study of genetic variation in coding regions [43–53]. Exon array findings correlate positively with RNA-Seq across most levels of transcript expression [54], and in some cases have less false-positive detection than RNA-Seq [55–57]. The analytical techniques for the exon arrays have been well established [56, 58–64].

Methods

Subject Enrollment

Subject enrollment occurred at a single clinical site at the University of Iowa. The University of Iowa and the Institutional Review Board approved the procedures in the study. The chronic SZ and BD type I outpatients aged 18–45 years provided consent for the study. All subjects (SZ, n = 30; BD, n = 30; and NC, n = 30) met the DSM-IV-R criteria and completed the study. Clinical assessments included the Scale for the Assessment of Positive Symptoms and Scale for the Assessment of Negative Symptoms (SAPS, SANS), medications, and drugs for the SZ and BD subjects, as well as the Young Mania Rating Scale (YMRS) and Hamilton Rating Scale for Depression (HAM-D or HRSD) for the BD subjects. These neuropsychiatric assessment data were analyzed and are reported separately for state-biomarker relationships. The mental state examination for the NC subjects consisted of the Mini-Mental State Examination. The outline of the study is shown in Figure 1. The demographics of the SZ, BD, and NC subjects are shown in online supplementary Table 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000485800) for the subjects’ age, sex, duration of illness, and ethnicity.

Whole blood samples were collected in Tempus Blood RNA tubes (Thermo Fisher Scientific) from the SZ, BD, and NC subjects at 3 visits spanning 3 months. For this report, the Tempus tubes from visits 2 and 4 were extracted and RNA gene expression was measured using Affymetrix exon arrays for both visits on all 90 subjects. High-quality RNA was extracted from the Tempus tubes using the manufacturer’s protocol, and quality was assessed on an Agilent Bioanalyzer using the RNA integrity number.

Human Exon Array for Biomarker Profiling

There are advantages to using the Affymetrix exon arrays [65] compared to whole transcriptome shotgun sequencing (RNA-Seq). At the time of sample collection, the cost factor was favorable for future clinical biomarker trials that would require hundreds of arrays compared to the cost of RNA-Seq for the entire validation. The processing time and data storage requirements as well are more favorable for a study this size using exon arrays. Although we and oth-
ers have previously found that SNPs can affect probe hybridization and consequently alter expression [44, 51, 52, 66], those probesets with common SNPs were eliminated from the final data set. The exon arrays were run at the Functional Genomics Laboratory, University of California, using the manufacturer’s protocol (Affymetrix, Santa Clara, CA, USA). The Functional Genomics Laboratory has run over 1,000 Affymetrix arrays with high-quality call rates.

**Data Analysis**

The Affymetrix exon array CEL files were imported into Partek Genomics using batch effect removal. The batch effect was based upon exon array scan dates, as usually 12 arrays were scanned in a single day. The mean intensity of probes was summarized at the probeset level. Probesets containing common SNPs were excluded from the import and downstream analysis. The resulting probesets were then median centered within each exon array sample individually (n = 180). A two-factor ANOVA was run for each probeset, using diagnosis, visit, and diagnosis × visit interaction. Visit was a repeated measure and was used to filter out genes that change significantly between visits. A false discovery rate (FDR) of 6 × 10⁻⁸ was established for diagnosis effect based upon 835,000 probesets. Three filters were used to select probesets from the ANOVA results that passed the FDR for diagnosis: (1) the most significant p values for BD compared to NC; (2) the most significant p values for BD compared to SZ; and (3) the most significant p values for SZ compared to NC. This resulted in a list of top probesets that was then reduced to probesets that mapped to known RefSeq genes. The top 100 RefSeq probesets for each of the three filters above were combined, and the resulting top 300 probesets were evaluated for biomarker signature.

**Biomarker Signature**

The modeling proceeded in four steps to select the most predictive panel of probesets out of the top 300 in each step for discriminating between groups:

- **Step 1**: NC versus BD + SZ
- **Step 2**: NC versus SZ
- **Step 3**: NC versus BD
- **Step 4**: SZ versus BD

Multivariate logistic regression modeling with forward stepwise selection (SAS PROC LOGISTIC) was used on the combined visit 2 and 4 data from the groups included in the step to select the probesets that were discriminating most strongly between the groups. We used forward stepwise regression to select probesets that differentiated two groups at a time (BD vs. SZ, BD vs. NC, and SZ vs. NC). A probeset was added to the model if the estimate was significant between visits. A false discovery rate (FDR) of 6 × 10⁻⁸ was established for diagnosis effect based upon 835,000 probesets. Three filters were used to select probesets from the ANOVA results that passed the FDR for diagnosis: (1) the most significant p values for BD compared to NC; (2) the most significant p values for BD compared to SZ; and (3) the most significant p values for SZ compared to NC. This resulted in a list of top probesets that was then reduced to probesets that mapped to known RefSeq genes. The top 100 RefSeq probesets for each of the three filters above were combined, and the resulting top 300 probesets were evaluated for biomarker signature.

**Table 1. Probesets that were found to reliably discriminate BD, SZ, and NC were assigned to known RefSeq transcripts**

| Biomarker panel (comparisons) | Affymetrix exon microarray transcript ID | Gene |
|-------------------------------|----------------------------------------|------|
| BD-NC                         | 2661992                                | OXTR |
| BD-NC                         | 3195034                                | PTGDS|
| BD-NC                         | 3333247                                | FADS2|
| BD-NC                         | 4048241                                | HLA-DRB5|
| BD-SZ                         | 2661992                                | OXTR |
| BD-SZ                         | 3333247                                | FADS2|
| BD-SZ                         | 3554818                                | CRIP2|
| BD-SZ-NC                      | 2418570                                | SLC44A5|
| BD-SZ-NC                      | 2545092                                | HADHA|
| BD-SZ-NC                      | 2647109                                | CPA3 |
| BD-SZ-NC                      | 2661992                                | OXTR |
| BD-SZ-NC                      | 2739160                                | CCDC109B|
| BD-SZ-NC                      | 2906720                                | TREM4|
| BD-SZ-NC                      | 3063536                                | TRIM4|
| BD-SZ-NC                      | 3195034                                | PTGDS|
| BD-SZ-NC                      | 3667890                                | HPR  |
| BD-SZ-NC                      | 3846538                                | EEF2 |
| BD-SZ-NC                      | 3908149                                | ZMYND8|
| BD-SZ-NC                      | 2401347                                | TCEA3|
| BD-SZ-NC                      | 2418570                                | SLC44A5|
| BD-SZ-NC                      | 2660617                                | IL5RA|
| BD-SZ-NC                      | 3329099                                | GYLTL1B|
| BD-SZ-NC                      | 3766893                                | DDX5 |

BD, bipolar disorder; SZ, schizophrenia; NC, normal control.

The visit 2 prediction model was then applied to the visit 4 data to assess utility for the second set of data, which included stability over time.

Further evaluation for each of the four panels included “leave-one-out” cross-validation where one subject was sequentially left out of the logistic model fit using the remaining subjects and then the predictability of the model for the excluded subject was assessed. This tested whether there were outliers in the data set that were driving the model.

**Quantitative PCR**

Transcripts were selected for quantitative PCR (qPCR) validation based upon significant differences using the ANOVA filter. We selected transcripts that represented a combination of the most...
significant ANOVA p values for SZ compared to NC and represented fold changes greater than 1.25. We initially selected qPCR to validate the exon array findings and later, after completing the entire biomarker panel analysis, used NanoString (see below) for validation. Standard SYBR Green qPCR methods previously described by the Functional Genomics Laboratory (University of California, Irvine) were used to confirm gene expression values derived from the exon array data set [31]. Briefly, in developing SYBR Green assays we use exon junction-crossing primers to eliminate any genomic DNA from amplification. We assess primers for amplification consistency by single dissociation peaks to represent a single region of cDNA amplification, and minimal primer-dimer formation that could interfere with the amplification signal. We require the primers to amplify genes in our samples at fewer than 35 cycles to be usable. We also run samples in triplicate, and use two housekeeping genes (SDHA and HPRT1) that have Ct within similar ranges to those of the genes being assayed.

**NanoString Gene Expression Platform**

A non-PCR-based approach to measuring RNA as a technical validation of the findings was used based upon NanoString technology, i.e., the nCounter® System (NanoString, Seattle, WA, USA) [68]. The NanoString platform requires a small quantity of RNA and provides digital counts of hybridization of mRNA to targets. The NanoString multiplex assay uses 100 ng of total RNA, and all of the RNA samples were processed at the UCI Genomics High-Throughput Facility. We selected a total of 44 custom NanoString probes designed to match the closest probeset on the Affymetrix exon array that was in the biomarker panel, and 6 NanoString probes for housekeeping genes (online suppl. Table 2). The resulting NanoString data were processed according to the manufacturer’s suggested protocol as outlined (NanoString Technologies, 2008–2012 #127). Each data point was preprocessed by the 6 positive controls (PC), the 8 negative controls (NC), and the 5 housekeeping (HK) genes as follows:

| Actual | Step 1 | Step 2 | Step 3 | Step 4 | Final call |
|--------|--------|--------|--------|--------|------------|
|        | NC     | SZ + BD | NC     | SZ     | BD         | NC | SZ | BD |
| Training visit 2 | 30 NC | 30 | 24 | 6 | 26 | 4 | 21 | 5 | 4 |
| 30 SZ | 3 | 27 | 1 | 29 | 29 | 1 | 3 | 26 | 1 |
| 30 BD | 1 | 29 | 1 | 29 | 1 | 29 | 1 | 1 | 28 |
| Testing visit 4 | 30 NC | 28 | 2 | 23 | 7 | 28 | 2 | 22 | 6 | 2 |
| 30 SZ | 1 | 29 | 0 | 30 | 29 | 1 | 1 | 28 | 1 |
| 30 BD | 1 | 29 | 0 | 30 | 0 | 30 | 1 | 0 | 29 |

The confusion matrices show the numbers of subjects correctly and incorrectly classified for each iteration of the classification. Step 1: 11 genes diagnostically differentiating BD + SZ from NC. Step 2: 5 genes diagnostically differentiating SZ from NC. Step 3: 4 genes diagnostically differentiating BD from NC. Step 4: 3 genes diagnostically differentiating SZ from BD. Final call: summary of the step 1, 2, 3, and 4 classifications. BD, bipolar disorder; SZ, schizophrenia; NC, normal control.

### Table 2. Prediction model trained on combined visit 2 and 4 data and tested on each visit individually

| Step 1 | Step 2 | Step 3 | Step 4 | Final call |
|--------|--------|--------|--------|------------|
| NC     | SZ     | NC     | SZ     | BD         | NC | SZ | BD |
| Training visit 2 | 30 NC | 30 | 24 | 6 | 26 | 4 | 21 | 5 | 4 |
| 30 SZ | 3 | 27 | 1 | 29 | 29 | 1 | 3 | 26 | 1 |
| 30 BD | 1 | 29 | 1 | 29 | 1 | 29 | 1 | 1 | 28 |
| Testing visit 4 | 30 NC | 28 | 2 | 23 | 7 | 28 | 2 | 22 | 6 | 2 |
| 30 SZ | 1 | 29 | 0 | 30 | 29 | 1 | 1 | 28 | 1 |
| 30 BD | 1 | 29 | 0 | 30 | 0 | 30 | 1 | 0 | 29 |

| Predicted | Visit 2 actual | Visit 4 actual | Both actual |
|------------|----------------|----------------|-------------|
| BD         | 28 | 1 | 4 | 29 | 1 | 2 | 57 | 2 | 6 |
| SZ         | 1 | 26 | 5 | 0 | 28 | 6 | 1 | 54 | 11 |
| NC         | 1 | 3 | 21 | 1 | 1 | 22 | 2 | 4 | 43 |

Accuracy: 83% | 88% | 86%  
Sensitivity (SZ): 87% | 93% | 90%  
Sensitivity (BP): 93% | 97% | 95%  
Specificity (NC): 70% | 73% | 72%  

BD, bipolar disorder; SZ, schizophrenia; NC, normal control.
Table 4. The overall results fitting a “leave-one-out” validation model to the remaining subjects show a stable clinical biomarker signature of mRNA expression across a 90-day test-retesting period with an accuracy greater than 87% for the retesting data at each of the model classification steps.

|               | BD + SZ vs. NC | SZ vs. NC | BD vs. NC | SZ vs. NC |
|---------------|----------------|-----------|-----------|-----------|
| (11-gene panel) | 97%            | 97%       | 97%       | 97%       |
| (5-gene panel) | 97%            | 97%       | 97%       | 97%       |
| (4-gene panel) | 97%            | 97%       | 97%       | 97%       |
| (3-gene panel) | 97%            | 97%       | 97%       | 97%       |

Actual visit 2 data

Sensitivity (SZ) 93% 97% - 97%
Sensitivity (BP) - 97% 97%
Specificity (NC) 100% 80% 87% -
Accuracy 96% 88% 92% 97%

“Leave-one-out” cross-validation

Sensitivity (SZ) 90% 93% - 90%
Sensitivity (BP) - 93% 93%
Specificity (NC) 83% 80% 80% -
Accuracy 88% 87% 87% 92%

BD, bipolar disorder; SZ, schizophrenia; NC, normal control.

The top 300 probesets from the Affymetrix exon microarray based upon ANOVA significance (online suppl. Table 3) were evaluated for biomarker signature (as described in Methods) for differentiating BD, SZ, and NC subjects. The resulting biomarker signature was composed of 23 probesets that condensed into 18 known RefSeq genes (biomarker panel; Table 1). The diagnostic logistic model was built in four steps, using the visit 2 transcripts shown in Table 1.

The resulting logistic predictive model based on visit 2 was then applied to the visit 4 data. The summary of individual steps in the construction of the biomarker gene panels is shown in Table 2. The diagnostic algorithm uses a four-step decision model: step 1, BD and SZ versus NC; step 2, SZ versus NC; step 3, BD versus NC; and step 4, SZ versus BD.

The 18-gene biomarker panels, using logistic regression modeling, correctly differentiated the three groups of subjects (SZ, BD type I, and NC) with high accuracy at visit 2 and visit 4. The visit 2 cut-point probabilities for the SZ-NC comparison were significantly correlated with the visit 4 cut-point probabilities (p < 0.0001) with r = 0.74 (95% CI 0.59–0.83) showing temporal stability (Table 3).

The initial model was developed for selecting stable probesets across visits and incorporated all subjects and visits to select the most informative probesets. To test that no single subject was overly influential in determining the model, the initial probesets were evaluated by a “leave-one-out” method, whereby a new model is fit to the remaining subjects, and the left-out subject is identified. “Leave-one-out” cross-validation is a model validation technique for assessing how the results of a statistical analysis will generalize to an independent data set. It is mainly used in settings where the goal is prediction to estimate how accurately a predictive model will perform in practice. This cross-validation was applied to the visit 2 data from each of the four probeset panels (Table 4). The results are very consistent with the actual data, and the “leave-one-out” analyses indicate that the models should be predictive when applied to independent data cohorts.

The AUC for each step was greater than 0.95, which is an indication of the high combined sensitivity and specificity of the classification into three groups (Table 5). When analyzing the same 18-gene biomarker panel and

Table 5. The diagnostic algorithm uses four individual steps, shown in each column

|               | BD + SZ vs. NC | SZ vs. NC | BD vs. NC | SZ vs. BD |
|---------------|----------------|-----------|-----------|-----------|
| (11-gene panel) | AUC = 0.994 (p < 0.0001) | AUC = 0.954 (p < 0.0001) | AUC = 0.974 (p < 0.0001) | AUC = 0.998 (p < 0.0001) |
| (5-gene panel) | AUC = 0.954 (p < 0.0001) | AUC = 0.974 (p < 0.0001) | AUC = 0.998 (p < 0.0001) | |
| (4-gene panel) | AUC = 0.974 (p < 0.0001) | AUC = 0.998 (p < 0.0001) | |
| (3-gene panel) | AUC = 0.998 (p < 0.0001) | | |

BD, bipolar disorder; SZ, schizophrenia; NC, normal control.

Results

The top 300 probesets from the Affymetrix exon microarray based upon ANOVA significance (online suppl. Table 3) were evaluated for biomarker signature (as described in Methods) for differentiating BD, SZ, and NC subjects. The resulting biomarker signature was composed of 23 probesets that condensed into 18 known RefSeq genes (biomarker panel; Table 1). The diagnostic logistic model was built in four steps, using the visit 2 transcripts shown in Table 1.

The resulting logistic predictive model based on visit 2 was then applied to the visit 4 data. The summary of individual steps in the construction of the biomarker gene panels is shown in Table 2. The diagnostic algorithm uses a four-step decision model: step 1, BD and SZ versus NC; step 2, SZ versus NC; step 3, BD versus NC; and step 4, SZ versus BD.

The 18-gene biomarker panels, using logistic regression modeling, correctly differentiated the three groups of subjects (SZ, BD type I, and NC) with high accuracy at visit 2 and visit 4. The visit 2 cut-point probabilities for the SZ-NC comparison were significantly correlated with the visit 4 cut-point probabilities (p < 0.0001) with r = 0.74 (95% CI 0.59–0.83) showing temporal stability (Table 3).

The initial model was developed for selecting stable probesets across visits and incorporated all subjects and visits to select the most informative probesets. To test that no single subject was overly influential in determining the model, the initial probesets were evaluated by a “leave-one-out” method, whereby a new model is fit to the remaining subjects, and the left-out subject is identified. “Leave-one-out” cross-validation is a model validation technique for assessing how the results of a statistical analysis will generalize to an independent data set. It is mainly used in settings where the goal is prediction to estimate how accurately a predictive model will perform in practice. This cross-validation was applied to the visit 2 data from each of the four probeset panels (Table 4). The results are very consistent with the actual data, and the “leave-one-out” analyses indicate that the models should be predictive when applied to independent data cohorts.

The AUC for each step was greater than 0.95, which is an indication of the high combined sensitivity and specificity of the classification into three groups (Table 5).
including the white blood cell counts as a covariate, the analysis slightly improved the diagnostic predictability of SZ versus NC, and of BP and SZ versus NC (data not shown). The data were not normalized to blood counts (CBC measurements) for our main data analysis reported in this paper, but this model confirmed that potential differences in white blood cell counts did not change our results as reported.

To account for potential medication effects (since many of the SZ and BD subjects were on stable dosages of antipsychotic or mood stabilizer medications at the time of blood draw), we analyzed the possibility that these medications could drive some of the differential transcription signatures. A subset of unmedicated BD (n = 3) and SZ (n = 1) cases were analyzed using the 18-gene diagnostics, which produced 100% accuracy in these 4 cases.

In addition, to test this possible explanation for the gene signature, we reanalyzed an even larger cohort of antipsychotic-free SZ patients using the Illumina gene expression microarray data sets [6]. The genome-wide RNA expression profiling was obtained with the Illumina HumanRef-8 V3 arrays for batch 1 and HumanRef-12 V3 arrays for batch 2 using Illumina’s standard protocol at the Illumina facility of the University of California, Los Angeles. The raw microarray data were available at gene expression omnibus (GEO) under accession No. GSE38485. Data set 1 includes antipsychotic-free SZ patients (n = 15) and healthy controls (n = 22). The 18-gene signature was extracted from the Illumina data set and analyzed by the same logistic regression equations as derived from the fit to our original data. Using this independent Illumina data set of gene expression data from the antipsychotic-free SZ subjects, the 18-gene diagnostics produced a ROC accuracy of 0.866 in medication-free patients below 30 years of age. The classification of antipsychotic-free patients with SZ was made using data from the Illumina HT-8 array [6]. SZ, schizophrenia; NC, normal control.

| Subjects                        | NC, n | SZ, n | ROC AUC | Sensitivity | Specificity |
|--------------------------------|-------|-------|---------|-------------|-------------|
| Antipsychotic free (all subjects) | 22    | 15    | 0.642   | 80.00%      | 59.10%      |
| Antipsychotic free (subjects aged <30 years) | 14    | 8     | 0.866   | 100.00%     | 71.40%      |

Using this data set from antipsychotic-free SZ subjects, the 18-gene diagnostics produced a ROC accuracy of 0.866 in medication-free patients below 30 years of age. The classification of antipsychotic-free patients with SZ was made using data from the Illumina HT-8 array [6]. SZ, schizophrenia; NC, normal control.

Table 6. The 18-gene signature was extracted from an independent data set of gene expression data and analyzed by the same logistic regression equations as derived from the fit to our original data

Table 7. qPCR results for candidate gene expression differences between SZ and NC

| Exon array (gene symbol) | p value (SZ vs. NC) | Ratio (SZ vs. NC) | qPCR | p value (SZ vs. NC) | Ratio (SZ vs. NC) |
|--------------------------|---------------------|-------------------|------|---------------------|-------------------|
| EDIL3                    | 1.04E-13            | 0.446             | EDIL3| 0.01418             | 0.425             |
| NRCAM                    | 1.37E-02            | 0.525             | NRCAM| 0.06127             | 0.663             |
| PTGDS                    | 1.41E-14            | 0.722             | PTGDS| 0.04731             | 0.695             |
| DSC2                     | 6.86E-04            | 1.592             | DSC2 | 0.00005             | 2.021             |
| NRG1                     | 1.14E-02            | 2.062             | NRG1 | 0.01021             | 1.979             |
| ITGA2B                   | 3.71E-02            | 2.088             | ITGA2B| 0.00007             | 2.269             |
| ITGB3                    | 2.65E-02            | 2.601             | ITGB3| 0.00005             | 2.065             |

qPCR, quantitative PCR; SZ, schizophrenia; NC, normal control.

qPCR Validation of the Exon Array

The transcripts were validated for SZ and NC using the qPCR methods described by Morgan et al. [31]. The transcripts for qPCR were selected based upon the differential expression results from the SZ-NC comparisons and upon visual inspection of exon expression differences across probesets that map to RefSeq transcripts. The qPCR results showed concordance (r = 0.86) between transcription techniques. The details on the methods and analysis of the antipsychotic-free patients are in the online supplementary Appendix. The duration of illness might allow us to test for more trait effects than state effects in the data set instead of using an arbitrary age cutoff for young subjects of below 30 years. Duration of illness is not entirely accurate, due to retrospective subject recall, which is why we chose age as our cut-point. Age and duration of illness are significantly collinear for BD subjects (r = 0.65; p < 0.001) and for SZ subjects (r = 0.62; p < 0.001). Further, we did not have access to the Illumina duration of illness data for comparison.

qPCR Validation of the Exon Array

The transcripts were validated for SZ and NC using the qPCR methods described by Morgan et al. [31]. The transcripts for qPCR were selected based upon the differential expression results from the SZ-NC comparisons and upon visual inspection of exon expression differences across probesets that map to RefSeq transcripts. The qPCR results showed concordance (r = 0.86) between transcription techniques. The details on the methods and analysis of the antipsychotic-free patients are in the online supplementary Appendix. The duration of illness might allow us to test for more trait effects than state effects in the data set instead of using an arbitrary age cutoff for young subjects of below 30 years. Duration of illness is not entirely accurate, due to retrospective subject recall, which is why we chose age as our cut-point. Age and duration of illness are significantly collinear for BD subjects (r = 0.65; p < 0.001) and for SZ subjects (r = 0.62; p < 0.001). Further, we did not have access to the Illumina duration of illness data for comparison.
exon array expression differences and qPCR (Table 7; Fig. 2). We used NanoString to test the complete panel of 18 biomarker genes.

**NanoString Platform Accuracy for Diagnostic Classification**

The NanoString platform was chosen to validate the biomarker panel using the entire panel as well as probesets mapping close to the original exon array probesets. With the NanoString data, the best multivariate logistic regression model for diagnosis at visit 2 was obtained by stepwise backward elimination from the full 23-probeset multivariate model to a reduced model with all included probesets significant at $p < 0.05$ or $p < 0.1$ to maintain an AUC above 0.9 (Table 8).

A cut-point for each reduced diagnostic model was found which optimized both sensitivity and specificity based on the visit 2 data, which reduced the useful probeset number to 12 (Table 9). The diagnostic model and cut-point were then applied to the visit 4 data to estimate the visit 4 sensitivity and specificity as well as the agreement between the visit 2 and the visit 4 diagnostic predictions.

**Comparison of Affymetrix Exon Array with NanoString Results**

The prediction accuracies for diagnosis were compared between the Affymetrix exon array and the NanoString platform. In general, for the exon array, the model performed equally well for visit 2 and visit 4 data due to the data driving the selection algorithm from the original platform. The visit 2/visit 4 agreement for the Af-

---

**Table 8.** The NanoString data set was analyzed by ANOVA, and the following 23 probesets representing 11 genes passed the initial ANOVA filter ($p < 0.1$)

| Probeset ID | Gene Symbol | Variable Number |
|-------------|-------------|-----------------|
| 2537112_SH3YL1 (30) | SH3YL1 | 30 |
| 2537128_SH3YL1 (61) | SH3YL1 | 61 |
| 2647127_CPA3 (35) | CPA3 | 35 |
| 2647122_CPA3 (47) | CPA3 | 47 |
| 2647124_CPA3 (65) | CPA3 | 65 |
| 2647119_CPA3 (69) | CPA3 | 69 |
| 2537112_SH3YL1 (30) | CRIP2 | 39 |
| 2537128_SH3YL1 (61) | CRIP2 | 58 |
| 2647127_CPA3 (35) | CRIP2 | 68 |
| 2647122_CPA3 (47) | CRIP2 | 68 |
| 2647124_CPA3 (65) | CRIP2 | 58 |
| 2647119_CPA3 (69) | CRIP2 | 68 |
| 2647119_CPA3 (69) | OXTR | 43 |
| 2647127_CPA3 (35) | OXTR | 55 |
| 2647122_CPA3 (47) | OXTR | 55 |
| 2647124_CPA3 (65) | OXTR | 55 |
| 2647119_CPA3 (69) | OXTR | 55 |
| 2537112_SH3YL1 (30) | TBC1D1 | 45 |
| 2537128_SH3YL1 (61) | TBC1D1 | 55 |
| 2647127_CPA3 (35) | TBC1D1 | 55 |
| 2647122_CPA3 (47) | TBC1D1 | 55 |
| 2647124_CPA3 (65) | TBC1D1 | 55 |
| 2647119_CPA3 (69) | TBC1D1 | 55 |

The format is: “Affymetrix Exon Array Probeset ID_Gene Symbol (variable number entered into regression).”

**Table 9.** Summary of NanoString cut-point diagnostic accuracy

| Significant probesets | NC vs. SZ/BP | NC vs. SZ | NC vs. BD | SZ vs. BD |
|------------------------|--------------|----------|----------|----------|
| 2537112_SH3YL1 (30)    | x            | x        | x        | x        |
| 2537128_SH3YL1 (61)    | x            | x        | x        | x        |
| 2647124_CPA3 (65)      | x            | x        | x        | x        |
| 2647119_CPA3 (69)      | x            | x        | x        | x        |
| 3554833_CRIP2 (68)     | x            | x        | x        | x        |
| 2661997_OXTR (43)      | x            | x        | x        | x        |
| 2906733_TREML4 (45)    | x            | x        | x        | x        |
| 2418590_SLC44A5 (51)   | x            | x        | x        | x        |
| 2401362_TCEA3 (70)     | x            | x        | x        | x        |

AUC 0.913 0.990 0.953 0.905
Visit 2 sensitivity 98.3% 96.6% 89.3% 86.2%
Visit 2 specificity 75.0% 96.4% 92.9% 82.1%
Visit 4 sensitivity 87.5% 75.0% 75.0% 57.1%
Visit 4 specificity 60.0% 80.0% 76.0% 85.7%
Visit 2/4 agreement 77.6% 76.0% 75.5% 64.2%

BD, bipolar disorder; SZ, schizophrenia; NC, normal control.

1 Format as explained in Table 8.
Table 10. Comparison of Affymetrix and NanoString results showing that the Affymetrix exon array had higher sensitivity and specificity for prediction

| NanoString probeset ID | NC vs. SZ/BD | NC vs. SZ | NC vs. BD | SZ vs. BD |
|------------------------|--------------|-----------|-----------|-----------|
|                        | Affymetrix ID | Nano-String | Affymetrix ID | Nano-String | Affymetrix ID | Nano-String | Affymetrix ID | Nano-String |
| 2537112_SH3YL1 (30)    | x            | x         | x         | x         |
| 2537128_SH3YL1 (61)    | x            | x         | x         | x         |
| 2647124 CPA3 (65)      | x            | x         | x         | x         |
| 2647119 CPA3 (69)      | 2647109      | x         | x         | x         |
| 3554833 CRIP2 (68)     | x            | x         | 3554818   | x         |
| 2418590 SLC44A5 (51)   | 2418570      | x         | 2418570   | x         |
| 2661997 OXTR (43)      | 2661992      | 2661992   | x         | 2661992   | x         |
| 2906733 TREML4 (62)    | 2906720      | x         |           |           |
| 3063538 TRIM4 (52)     | 3063536      | x         | x         | x         |
| 2723770 TBC1D1 (55)    | x            |           |           |           |
| 3195045 PTGDS (59)     | 3195034      | x         | 3195034   | x         |
| 2401362 TCEA3 (70)     |              | 2401347   | x         |           |
| 3667896,97 HPR         | 3667890      |           |           |           |
| 3908171 ZMYND8         | 3908149      |           |           |           |
| 2545100 HADHA          | 2545092      |           |           |           |
| 2739191 CCDC109B       | 2739160      |           |           |           |
| 3846545 EEF2           | 3846538      |           |           |           |
| 3333251,56,58,62,69,70,74 FADS2 | 3333247 | 3333247    |           |
| 4048243,52 HLA-DRB5    | 4048241      |           |           |           |
| 3329128 GYLT1B         | 3329099      |           |           |           |
| 2660633/41 IL5RA       | 2660617      |           |           |           |
| 3766938 DDX5           | 3766893      |           |           |           |
| AUC^1                  | 0.994        | 0.913     | 0.954     | 0.990     | 0.974       | 0.953       | 0.998       | 0.905      |
| Visit 2 sensitivity    | 93.3%        | 98.3%     | 96.7%     | 96.6%     | 96.7%       | 89.3%       | 96.7%       | 86.2%      |
| Visit 2 specificity    | 100%         | 75.0%     | 83.3%     | 96.4%     | 86.7%       | 92.9%       | 100%        | 82.1%      |
| Visit 4 sensitivity    | 96.7%        | 87.5%     | 100%      | 75.0%     | 93.3%       | 75.0%       | 96.7%       | 57.1%      |
| Visit 4 specificity    | 93.3%        | 60.0%     | 80%       | 80.0%     | 100.0%      | 76.0%       | 100%        | 85.7%      |
| Visit 2/4 agreement    | 93.3%        | 77.6%     | 86.7%     | 76.0%     | 88.3%       | 75.5%       | 100%        | 64.2%      |

BD, bipolar disorder; SZ, schizophrenia; NC, normal control. ^1 The AUC was for combined visit 2 and 4 modeling, and each visit was evaluated for predictions individually.
The fymetrix exon array was significantly higher than for the NanoString reproducibility diagnosis classification (two-tailed paired t test, \( p = 0.046 \)). These results show that the test-retest reproducibility of the algorithm using the same subjects was best when using the original platform (Table 10), although there was general agreement across platforms.

In comparing the qPCR, exon array, and NanoString results, 5 of 7 genes tested by qPCR passed with significant p values, while all genes were concordant with fold changes between the exon array and qPCR results. The biomarker panel was developed more than 2 years after the initial qPCR approach to validate the findings on the exon array. Therefore, only 7 genes were selected by qPCR for confirmation of the exon array findings. Instead of qPCR, the panel of NanoString markers was used for validation of the panel of biomarkers. The NanoString data set confirmed that the best prediction was based upon 10 NanoString genes of the original 18 exon array genes.

### Bioinformatic Analysis of the Biomarker Panel

A recent mega-analysis of differentially expressed genes in SZ across 9 studies was conducted in blood-based transcriptomics [35]. There were 1,624 genes that survived the FDR that were compared to the top 122 genes identified by ANOVA in the present study. The formula for the expected number of genes was calculated as:

\[
\text{Expected gene number overlaps} = \frac{\text{observed genes in list 1} \times \text{observed genes in list 2}}{24,000}
\]

This formula yields an expected number of 8.2 genes, while the actually observed number was 9 genes; we conclude that the overlap was not exceeding chance level. Interestingly, 2 mitochondrial genes were found among these top 9, and they agreed in fold change direction across the two studies (Table 11): (1) mitochondrial ribosomal protein L42 (MRPL42) and (2) transcription factor B1, mitochondrial (TFB1M).

### Table 11. Overlap between a mega-analysis of dysregulated genes in blood [35] and the current study

| Gene symbol     | Gene product                                | Mean difference | FDR q value | Gene symbol | p value (SZ vs. NC) | Ratio (SZ vs. NC) |
|-----------------|---------------------------------------------|----------------|-------------|-------------|--------------------|------------------|
| FAM118A         | family with sequence similarity 118, member A | -0.37          | 5.90E-04    | FAM118A     | 4.17E-13           | 0.58             |
| MRPL42          | mitochondrial ribosomal protein L42         | 0.27           | 1.90E-02    | MRPL42      | 0.000535           | 1.24             |
| PHF14           | PHD finger protein 14                       | 0.26           | 2.50E-02    | PHF14       | 3.09E-14           | 0.49             |
| PHP3            | pleckstrin homology domain interacting protein | 0.29           | 9.10E-03    | PHP3        | 4.66E-29           | 0.59             |
| PLB1            | phospholipase B1                           | 0.26           | 3.40E-02    | PLB1        | 2.70E-13           | 1.52             |
| SLC22A4         | solute carrier family 22 (organic cation/zwitterion transporter), member 4 | 0.34       | 3.30E-03    | SLC22A4     | 0.039619           | 1.14             |
| STX2            | syntaxin 2                                  | 0.28           | 1.30E-02    | STX2        | 1.49E-05           | 0.81             |
| TFB1M           | transcription factor B1, mitochondrial      | -0.5           | 3.60E-02    | TFB1M       | 1.11E-05           | 0.79             |
| TNFRSF21        | tumor necrosis factor receptor superfamily, member 21 | -0.31       | 3.70E-03    | TNFRSF21    | 1.96E-13           | 0.53             |

FDR, false discovery rate; SZ, schizophrenia; NC, normal control.
while an opposite relationship was seen for PHF14 (downregulated in SZ [-2.01] and upregulated in BD [2.95]).

MKL2 is a proto-oncogene which is widely distributed, highly expressed in brain regions such as the dentate gyrus (Allen Institute Brain Science [70]), and associated with microcephaly [71]. The MKL2 gene consists of multiple exons many of which are downregulated in SZ and not significantly changed in BD. The exon levels in blood for MKL2 were differentially expressed in SZ, although not in the top 300 genes (Fig. 4). The downstream effects on MKL2-regulated genes in the top biomarker classification genes were in the expected directions, e.g., there were decreased fold changes seen in genes regulated by MKL2 in SZ (ACTA2, FADS2, and CPA3), while the same set was upregulated in BD.

Two additional genes in the biomarker panels, i.e., PTGDS (prostaglandin D2 [PGD2] synthase) and FADS2 (fatty acid desaturase 2), were also found to be candidate genes in the literature. PTGDS expression was reduced in BD PBMCs [72], also in the present study ($p = 0.000271$; fold change $-1.23$), and it was down in SZ as well ($p = 9.04E-12$; fold change $-1.52$). In BD and SZ there appears to be a downregulation of PTGDS, which also was ranked higher in the top biomarker classification genes.

GWASdb contains lists of genes that have been associated with either or both disorders by GWAS. There was an enrichment of the overlap of genes found to be differentially expressed and associated with disorder. GWAS, genome-wide association study; BD, bipolar disorder; SZ, schizophrenia.

### Table 12. Overlap between GWASdb v2 [69] and the current study of differentially expressed genes in BD and SZ

| Overlap BD and GWASdb v2 | Overlap SZ and GWASdb v2 |
|--------------------------|--------------------------|
| CNTNAP2                  | CDC42BPB                 |
| TBC1D1                   | KANK1                    |
| EDIL3                    | PRICKLE1                 |
| LRRC16A                  | SLC4A5                   |
| TCEA3                    | FCER2                    |
| NRCAM                    | AK5                      |
| PAX5                     | DSP                      |
| EXO1                     | DNAH6                    |
| JUP                      | MKL2                     |
| C22orf34                 | NPAS2                    |
| SUMF1                    | PAX5                     |
| PAX5                     | LAPTM4B                  |
| EXO1                     | LRRC16A                  |
| JUP                      | ADARB2                   |

GWASdb contains lists of genes that have been associated with either or both disorders by GWAS. There was an enrichment of the overlap of genes found to be differentially expressed and associated with disorder. GWAS, genome-wide association study; BD, bipolar disorder; SZ, schizophrenia.
The FADS2 and PTGDS genes work in the biosynthesis of the fatty acid pathway and converge on key molecules in BD such as arachidonic acid. HADHA was significantly increased in BD ($p = 4.74E^{-08}$; fold change 1.67) and was not changed in SZ. HADHA is closely related to FADS2 and HADHA in the fatty acid pathway (Fig. 5) and along with PTGDS participates in the biosynthesis and degradation of unsaturated fatty acids, an important pathway implicated in BD and SZ.

Discussion

To determine stable temporal biomarkers, this study evaluated whole blood gene expression at two different time points using the same subjects (SZ, BD, and NC) for differential diagnosis. The diagnostic algorithm used logistic regression modeling and a total of 18 uniquely expressed exons within known mRNA transcripts. The model discriminated SZ and BD from each other, as well as both from healthy controls in four steps. The upper limit of accuracy achieved in this biomarker study was 88%, using an independent visit of the same patients. When using the “leave-one-out” evaluation algorithm, the results were very consistent with the actual data; thus, the “leave-one-out” analyses indicated that the models were not driven by outliers and that they should be predictive when applied to independent data cohorts.

It is expected that the application of these panels to first-episode or prodromal subjects may improve prediction for those subjects that ultimately convert to either illness, as well as for the millions of patients worldwide that have not received any clear diagnosis of their ongoing disorder. This will require an additional validation study of the biomarker signatures with a larger cohort in a follow-on project.

The differences in expression of 3 genes (PTGDS, FADS2, and HADHA) related to polyunsaturated fatty acid (PUFA) and prostaglandin biosynthesis were used for the final biomarker panels to differentiate between SZ, BD, and NC. Previously, these genes have been associated with psychiatric disorders such as BD, major affective disorder, SZ, and anxiety. PTGDS is involved in the synthesis of PGD$_2$ from PGH$_2$, the cyclooxygenase-mediated product of arachidonic acid which is a PUFA [4]. PTGDS is a top anxiety gene modulated by changes in PUFA (omega-3 fatty acid docosahexaenoic acid) [73] on the convergent functional genomics scale. Increased expression of FADS2 has been found in SZ and BD brains post-
mortality [74, 75]. FADS2 activity is increased in BD and is associated with suicidal behavior [76].

In the present study, we found an increased expression of FADS2 in BD, in agreement with the FADS2 findings reported. The increased activity of FADS2 could reduce PUFA levels of both arachidonic acid and eicosapentaenoic acid by promoting conversion to longer-chain fatty acids, shown in both the n–3 and the n–6 pathway (Fig. 5). Thus, PUFA supplementation with n–3 fatty acids in mood disorder was effective in reducing mood symptoms in 4 out of 7 well-controlled studies [76]. The expression data for FADS2, while interesting, could be subject to dietary influence, such as amounts and types of daily dietary intake of fatty acids, the timing of intake, and also medication effects on these genes. Further, genetics plays a significant role, especially in modulating levels of fatty acids and FADS2 expression. Another limitation to assessing these genes as representing actual pathophysiological markers is that, potentially, stress could modulate the biomarker panel genes. Many patients with BD and SZ experience higher levels of stress than controls, which might explain differences in immune cell activation and

---

**Fig. 5.** Modified KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway labels for FADS2 and HADHA participate in the conversion of polyunsaturated fatty acids and fatty acid β-oxidation.
prostaglandin synthesis. We examined our biomarker panel of 18 genes in our unpublished stress data set (M. Martin and M.P.V.) using the same exon array approach and Tempus tube approach on healthy volunteers who underwent sleep deprivation and 9 repeated blood draws over 54 h, i.e., every 6 h. We checked our results for the healthy controls and found that 4 transcripts that passed Bonferroni corrections were affected by time of day and, potentially, stress induction as well (DDX5, EEF2, HADHA, and CCDC109B). However, these 4 genes did not vary in the present study, even though in the stress data set these genes varied by time of day. Taken together, although these 4 genes were dysregulated as a consequence of time of day and sleep deprivation, these genes in the present study were stable across 8 weeks of time, and would have been expected to show some fluctuation with stress levels or time of day.

Several design points could be potential limitations as well. First, the study was not designed to test for treatment effects or treatment response. Although we have some psychiatric ratings available for the subjects, a feasible approach would be to identify treatment responders versus nonresponders using a within-subject design, comparing the severity of psychotic symptoms before and after 8 weeks of treatment, and correlating stably expressed biomarkers with response to treatment. This alternative approach would yield useful information, and is planned for a follow-on analysis of the data to explore biomarkers of treatment response. An inspection of the “treatment responders” in the study showed that the majority of patients did not change their medications, were clinically stable, and maintained similar psychiatric ratings across the 8 weeks. Further, for differentiating diseased from nondiseased groups, we adopted an outpatient case-control analysis. Another approach that could yield potential data in a future test of the biomarker panel is whether unaffected siblings of psychiatric patients could be reliably differentiated by the panel. This approach could be utilized as well in future studies. The current biomarker panel could also be used on subjects with major depressive disorder to examine if there is some coherence to a subclassification into more psychotic (in the SZ group) or more affective disorders (in the BD group) for aiding in potential treatments for these patients. These directions will go far in providing useful information to clinicians, researchers, and patients to guide our understanding of these illnesses.

A tremendous effort has been expended into GWAS of SZ [77] and BD [78], and it is recognized that there is a large number of common variants contributing to the polygenic susceptibility for these disorders. Estimates from several hundred genes of small effect size, as published in the largest international genetic study of SZ [79], to the possibility that thousands of genes are involved in the pathogenesis of SZ were made [80]. We have highlighted several genes that contribute towards this susceptibility using transcription analysis (Table 12), finding some overlap between GWAS variants and differential gene expression. Our present biomarker results overlap with a genetic database of genes implicated in either BD or SZ or both from a database of GWAS-curated genes (GWASdb v2 [69]). We found a significant overlap with our list of 122 differentially expressed genes for BD and SZ that were temporally stable (Table 12). The overlap of 22 genes suggests that peripheral biomarkers of either SZ or BD may have some genetic component that could drive differential expression. This leaves open the possibility that a number of serum proteins [81–85] and transcripts will advance as biomarkers.

Additionally, 2 upstream transcription factors merit further investigation, i.e., REL and MKL2, which appear to oppositely regulate genes in BD and SZ. The downstream targets of the genes were used to differentially diagnose subjects with BD and SZ. These proto-oncogenes have not previously been associated with psychiatric disorders. The expression of these 2 transcription factors (REL and MKL2) was studied in the cerebral cortex and shown to be expressed in microglia and endothelial cell types at higher levels than in neurons and astrocytes [86]. This raises the possibility that blood transcriptomics is mirroring some of the microglial/endothelial cell activity in the brain. It is known that peripheral cells can interact with brain microglia and endothelial cells.

There are prior reports supporting the directions of gene expression changes found in this biomarker study. For example, there was a consistent increase in expression of IL5RA (interleukin 5 receptor, alpha) in lithium-treated subjects with BD in PBMCs that passed a strict FDR [87]. In the final biomarker panel, we also found a trend for an increase in IL5RA expression in BD (p value for FDR = 0.056; fold change 1.16); however, IL5RA expression in SZ was significantly decreased and passing the FDR (p value for SZ vs. NC = 2.65E–08; fold change 1.59). Regarding PLB1 (phospholipase B1) in PBMCs, lithium decreased its expression (–1.17 fold change), passing the FDR [87] in PBMCs, while in the present study, PLB1 was significantly decreased in BD by –1.19 and was not significantly increased in SZ (p = 0.06; fold change 1.16). It is unlikely that some expression in the biomarker panel might be due to lithium treatment, since only 2 BD subjects were lithium treated in this study. An-
other ramification of using biomarkers is to provide a method for monitoring drug efficacy and other appropriate early psychosocial interventions for mental disorders. In a planned separate analysis, we will further correlate the phenotypic neuropsychiatric rating data obtained from each patient along with the gene expression data. Over 100,000 adolescent Americans suffer from symptoms of psychosis each year, as well as millions of patients worldwide that have not received any clear differential diagnosis of their ongoing disorder; yet, currently, there are no biomarker tests that are FDA approved to classify SZ or BD. There is a serious need for “objective” clinical laboratory tests for an early diagnosis of these mental disorders, since today these disorders may typically take months or even years to reach a diagnosis and for patients to receive effective treatment. The lag in treatment is associated with an increase in suicide rates and recurrent episodes of psychosis and mood dysregulation. There is a large increase in deaths reported among first-episode psychotic subjects due to lack of treatment after the first year of illness [1]. Thus, it is important to have objective biomarkers to help implement treatment at an early stage. One estimate of the direct and indirect annual costs in the USA for SZ is USD 174 billion [88], with an additional cost of USD 151 billion for BD [89]. Biomarker signatures could lead to faster and more accurate diagnoses, reducing the duration of untreated psychosis, suicidality, and cognitive decline and adding to an understanding of the shared and unique pathophysiology of each disorder. The blood test results that are described in this paper, if further validated in a larger number of subjects, will offer molecular diagnostic support for psychiatrists’ clinical evaluation with rapid clinical laboratory test results.

Acknowledgements

The authors wish to thank Nancy J. Hollenbeck at the University of Iowa for subject recruitment and enrollment for this study.

Statement of Ethics

The University of Iowa and the Institutional Review Board approved the procedures in the study. The chronic SZ and BD type I outpatients aged 18–45 years provided consent for the study.

Disclosure Statement

A SBIR Phase I project “Gene expression exon array biomarkers to diagnose schizophrenia” (R43 MH090806) was awarded (T.W.O.) for developing a blood-based commercial biomarker test for psychiatric disorders. The authors (M.P.V. and T.W.O.) are officers of Laguna Diagnostic, LLC, and co-inventors of a patent application to commercialize the results presented.

References

1 Schoenbaum M, Sutherland JM, Chappel A, Azrin S, Goldstein AB, Rupp A, Heinsen RK: Twelve-month health care use and mortality in commercially insured young people with incident psychosis in the United States. Schizophr Bull 2017;43:1262–1272.
2 Kebrir O, Chaumette B, Rivollier F, Miozzo F, Lemieux Perreault LP, Barhadi A, Provost S, Plaze M, Bourgin J; ICAAR Team, Gaillard R, et al: Methylomic changes during conversion to psychosis. Mol Psychiatry 2017;22:512–518.
3 Schiavone S, Trabace L: Inflammation, stress response, and redox dysregulation biomarkers: clinical outcomes and pharmacological implications for psychosis. Front Psychiatry 2017;8:203.
4 Begemann M, Sargin D, Rossner MJ, Bartels C, Theis F, Wichert SP, Stender N, Fischer B, Sperling S, Stawicki S, et al: Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches. Mol Med 2008;14:546–552.
5 Bowden NA, Weidenhofer J, Scott RJ, Schall U, Todd J, Michie PT, Tooney PA: Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr Res 2006;82:175–183.
6 de Jong S, Boks MP, Fuller TF, Strengman E, Janson E, de Kovel CG, Ori AP, Vi N, Mulder F, Blom JD, et al: A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genes. PLoS One 2012;7:e39498.
7 Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sásik R, Khanlou N, Han M, Liew CC, Tsuang MT: Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci USA 2005;102:15533–15538.
8 Middleton FA, Pato CN, Gentile KL, McGann L, Brown AM, Trauzzi M, Diab H, Morley CP, Medeiros H, Macedo A, et al: Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches. Am J Med Genet B Neuropsychiatr Genet 2005;136B:12–25.
9 Naydenov AV, MacDonald ML, Ongur D, Konradi C: Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. Arch Gen Psychiatry 2007;64:555–564.
10 Perl O, Strous RD, Dranikov A, Chen R, Fuchs S: Low levels of α-4-nicotinic acetylcholine receptor mRNA on peripheral blood lymphocytes in schizophrenia and its association with illness severity. Neuropsychobiology 2006;53:88–93.
11 Sanders AR, Göring HH, Duan J, Drigalenko EI, Moy W, Freda J, He D, Shi J; MGS, Gejman PV: Transcriptome study of differential expression in schizophrenia. Hum Mol Genet 2013;22:5001–5014.
12 Yao Y, Schröder J, Karlsson H: Verification of proposed peripheral biomarkers in mononuclear cells of individuals with schizophrenia. J Psychiatr Res 2008;42:639–643.
13 Maes OC, Xu S, Yu B, Cherkikov HM, Wang E, Schipper HM: Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging 2007;28:1795–1809.
Exon Array Biomarkers for the Differential Diagnosis of SZ and BD

Mol Neuropsychiatry 2017;3:197–213
DOI: 10.1159/000485800

52 Gazomar ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolea DL, Dolan ME, Cox NJ: SCAN: SNP and copy number annotation. Bioinformatics 2010;26:259–262.

53 Pradervand S, Paullussen A, Thomas I, Weber J, Wirapati P, Hagensuchle O, Harshman K: Affymetrix Whole-Transcript Human Gene 1.0 ST array is highly concordant with standard 3′ expression arrays. Biotechniques 2008;44:759–762.

54 Agarwal A, Koppstein D, Rozovsky J, Sbener A, Habecker L, Hilton IJ, Sassidhara R, Reinke V, Waterston RH, Gerstein M: Comparison and calibration of transcriptome data from RNA-Seq and tiling arrays. BMC Genomics 2010;11:383.

55 Bradford JR, Hey Y, Yates T, Li Y, Pepper SD, Roe CA, Clark TA, Chen TX, Schweitzer AC, Jiang H, Wilhelmy J, Clark TA, Kapur K, Nurnberger A, Sviridova O, Lehrach H, Vingron M, et al: Prediction of alternative isoforms from exon expression levels in RNA-Seq experiments. Nucleic Acids Res 2010;38:e112.

56 Liu S, Lin L, Jiang P, Wang D, Xing Y: A comparison of RNA-Seq and high-density exon array for detecting differential gene expression between closely related species. Nucleic Acids Res 2011;39:578–588.

57 Richard H, Schulz MH, Sultan M, Nürnberg A, Schirrner S, Balzerdeit D, Dagan E, Ra-sche A, Lehrah C, Vingron M, et al: Prediction of alternative isoforms from exon expression levels in RNA-Seq experiments. Nucleic Acids Res 2010;38:e112.

58 Kapur K, Jiang H, Xing Y, Wong WH: Cross-hybridization modeling on Affymetrix exon arrays. Bioinformatics 2008;24:2887–2893.

59 Kapur K, Xing Y, Ouyang Z, Wong WH: Exon arrays provide accurate assessments of gene expression. Genome Biol 2007;8:R82.

60 Xing Y, Kapur K, Wong WH: Probe selection and expression index computation of Affymetrix Exon Arrays. PLoS One 2006;1:e88.

61 Xing Y, Ouyang Z, Kapur K, Scott MP, Wong WH: Assessing the conservation of mamma-lian gene expression using high-density exon arrays. Mol Biol Evol 2007;24:1283–1285.

62 Xing Y, Stoilov P, Kapur K, Han A, Jiang H, Shen S, Black DL, Wong WH: MADS: a new and improved method for analysis of differential alternative splicing by exon-tiling microarrays. RNA 2008;14:1470–1479.

63 Lin L, Liu S, Brockway H, Seok J, Jiang P, Wong WH, Xing Y: Using high-density exon arrays to profile gene expression in closely related species. Nucleic Acids Res 2009;37:e90.

64 Shen S, Warzecha CC, Carstens RP, Xing Y: MADS+: discovery of differential splicing events from Affymetrix exon junction array data. Bioinformatics 2010;26:268–269.

65 Xu W, Seok J, Mindrinos MN, Schweitzer AC, Jiang H, Wihlem J, Clark TA, Kapur K, Xing Y, Faham M, et al: Human transcriptome array for high-throughput clinical studies. Proc Natl Acad Sci USA 2011;108:3707–3712.

66 Duan S, Huang RS, Zhang W, Bleibel WK, Roe CA, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, et al: Genetic architecture of transcript-level variation in humans. Am J Hum Genet 2008;82:1101–1113.

67 Pepe MS: The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford statistical science series. Oxford/New York, Oxford University Press, 2003, xvi, p 302.

68 Mamdani F, Rollins B, Morgan L, Myers RM, Barchas JD, Schatzberg AF, Watson SJ, Akil H, Potkin SG, Bunney WE, et al: Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder. Transl Psychiatry 2015;5:e636.

69 Li MJ, Liu Z, Wang P, Wong MP, Nelson MR, Kocher JP, Yeager M, Sham PC, Chanock SJ, Xia Z, et al: GWASdb v2: an update database for human genetic variants identified by genome-wide association studies. Nucleic Acids Res 2015;43:D996–D1005.

70 Hawrylcz MJ, Lein ES, Guilllozet-Bongaarts AL, Shen EH, Ng L, Miller JA, van de Lage-maat LN, Smith KA, Ebbert A, Riley ZL, et al: An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 2012;489:391–399.

71 Ramos EI, Bien-Willner GA, Li J, Hughes AE, Giacalone J, Chassonl S, Kulkarni S, Parma-cck M, Cole FS, Druley TE: Genetic varia-tion in MKL2 and decreased downstream PCTAIRE1 expression in extreme, fatal primary human microcephaly. Clin Genet 2014; 85:423–432.

72 Munkholm K, Peijs L, Kessing LV, Vinberg M: Reduced mRNA expression of PTGIS in peripheral blood mononuclear cells of rapid-cycling bipolar disorder patients compared with healthy control subjects. Int J Neuropsychopharmacol 2014;18:pyu101.

73 Le-Niculescu H, Balarayan T, Patel SD, Ayalew M, Gupta J, Kuczenski R, Shekhar A, Schork N, Geyer MA, Niculescu AB: Convergent functional genomics of anxiety disor-ders: translational identification of genes, bio-markers, pathways and mechanisms. Transl Psychiatry 2011;1:e9.

74 Liu Y, McNamara RK: Elevated delta-6 desaturase (FADS2) gene expression in the pre-frontal cortex of patients with bipolar disorder. J Psychiatr Res 2011;45:269–272.

75 Liu Y, Jandacek R, Rider T, Tao P, McNamara RK: Elevated delta-6 desaturase (FADS2) expression in the postmortem prefrontal cortex of schizophrenic patients: relationship with fatty acid composition. Schizophr Res 2009; 109:113–120.

76 Evans SJ, Prossin AR, Harrington GJ, Kamali M, Ellingrod VL, Burant CF, McNiss MG: Fats and factors: lipid profiles associate with personality factors and suicidal history in bi-polar subjects. PLoS One 2012;7:e29297.

77 Schizophrenia Working Group of the Psychi-atric Genomics Consortium: Biological in-sights from 108 schizophrenia-associated ge-netic loci. Nature 2014;511:421–427.

78 Hou L, Bergen SE, Akula N, Song J, Hultman CM, Landén M, Adli M, Alida M, Ardaud R, Arias B, et al: Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Hum Mol Genet 2016;25:3383–3394.

79 Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, Sklar P: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460:748–752.

80 Framer M, Roussos P, Sieberks SK, Johnson JS, Kavathigh DH, D’Amato TM, Ruderfer DR, Oh EC, Topol A, Shah HR, et al: Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci 2016;19:1442–1453.

81 Chan MK, Gottschalk MG, Haenisch F, To-makis J, Ruland T, Rahmone H, Guest PC, Bahn S: Application of blood-based protein biomarker strategies in the study of psychiat-ric disorders. Prog Neurobiol 2014;122:45– 72.

82 Chan MK, Krebs MO, Cox D, Guest PC, Yoklen RH, Rahmone H, Rothermundt M, Steiner J, Leweke FM, van Beveren NJ, et al: Development of a blood-based molecular bio-marketer test for identification of schizophrenia before disease onset. Transl Psychiatry 2015;5:e601.

83 Haenisch F, Cooper JD, Reif A, Klett-Schnei-der S, Steiner J, Leweke FM, Rothermundt M, van Beveren NJ, Crespo-Facorro B, Niebuhr DW, et al: Towards a blood-based diagnostic panel for bipolar disorder. Brain Behav Immun 2016;52:49–57.

84 SCarr E, Millan MJ, Bahn S, Bertolino A, Turk CW, Kapur S, Möller HJ, Dean B: Bio-markers for psychiatry: the journey from fant-asy to fact, a report of the 2013 CINP Think Tank. Int J Neuropsychopharmacol 2015; 18:py042.

85 Tomasik J, Schwarz E, Guest PC, Bahn S: Blood test for schizophrenia. Eur Arch Psychi-atry Clin Neurosci 2012;262(suppl 2): S79–S83.

86 Zhang T, Chen K, Sloan SA, Bennett ML, Schizzi AR, O’Keef S, Phatnanji HP, Guar-nieri P, Caneda C, Ruedtisch N, et al: An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 2014;34: 11929–11947.

87 Anand A, McLintick JN, Murrell J, Karne H, Nurnberger JI, Edenberg HJ: Effects of lithi-um monotherapy for bipolar disorder on gene expression in peripheral lymphocytes. Mol Neuropsychiatry 2016;2:115–123.

88 Cloutier M, Aigbogun MS, Guerin A, Nitu-lucescu R, Ramanakumar AV, Kamat SA, Delu-cia M, Duffy R, Legacy SN, Henderson C, et al: The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry 2016; 77:764–771.

89 Dower SC: An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord 2011;129:79–83.